RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis

Xiaomeng Yao, Yunkai Lin, Pingping Chen, Mengyou Xu, Mengmiao Pei, Xinru Fan, Huibo Feng, Xinhao Xing, Jiaqi Guo, Yang Liu, Xinzhu Quan, Yufei Pan, Yexiong Tan, Huabang Zhou, Liwei Dong, Hui Wang, Heping Hu · 2026

Read RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis by Xiaomeng Yao, Yunkai Lin, Pingping Chen, Mengyou Xu, Mengmiao Pei, Xinru Fan, Huibo Feng, Xinhao Xing, Jiaqi Guo, Yang Liu, Xinzhu Quan, Yufei Pan, Yexiong Tan, Huabang Zhou, Liwei Dong, Hui Wang, Heping Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197568.txt.

Description

Yao and coauthors find a gene that drives drug resistance in liver cancer. A targeted drug is now a cornerstone for advanced liver cancer. Resistance to it soon cuts its clinical benefit, though. The team screened for genes tied to that resistance.

One gene, called RPRD1A, stood out as a top candidate. Raising it made cancer cells far less sensitive to the drug. Cutting it restored drug response in those cells. The gene competes with a partner for binding in gene copying. That contest lifts a growth and adhesion signal axis. Blocking that axis may restore drug gains.

Catalog record

CREATORXiaomeng Yao, Yunkai Lin, Pingping Chen, Mengyou Xu, Mengmiao Pei, Xinru Fan, Huibo Feng, Xinhao Xing, Jiaqi Guo, Yang Liu, Xinzhu Quan, Yufei Pan, Yexiong Tan, Huabang Zhou, Liwei Dong, Hui Wang, Heping Hu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13197568

Browse the full library · About the Tower of Babel